HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1

被引：0

作者：

Braso-Maristany, F. ^{[1
]}

Griguolo, G. ^{[2
]}

Chic, N. ^{[3
]}

Pare Brunet, L. ^{[3
]}

Galvan, P. ^{[4
]}

Dieci, M. V. ^{[5
]}

Miglietta, F. ^{[6
]}

Giarratano, T. ^{[7
]}

Martinez-Saez, O. ^{[8
]}

Marin, M. ^{[8
]}

Vidal Losada, M. J. ^{[9
]}

Adamo, B. ^{[10
]}

Munoz, M. ^{[11
]}

Vivancos, A. ^{[12
]}

Villagrasa Gonzalez, P. ^{[13
]}

Parker, J. ^{[13
]}

Perou, C. M. ^{[14
]}

Conte, P. F. ^{[15
]}

Prat, A. ^{[16
]}

Guarneri, V. ^{[17
]}

机构：

[1] IDIBAPS Inst Invest Biomed August Pi & Sunyer, Dept Oncol, Barcelona, Spain

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[3] Reveal Genom SL, Dept Sci, Barcelona, Spain

[4] IDIBAPS August Pi & Sunyer Biomed Res Inst, Dept Med Oncol, Barcelona, Spain

[5] Univ Padua, DiSCOG, Padua, Italy

[6] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol, Padua, Italy

[7] IOV Ist Oncologico Veneto IRCCS, Dept Oncol, Padua, Italy

[8] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[9] Hosp Clin Barcelona, Breast Canc, Barcelona, Spain

[10] Hosp Clin Prov Barcelona, Breast Canc Dept, Barcelona, Spain

[11] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[12] Vall Hebron Univ sity Hosp, Genom Dept, Barcelona, Spain

[13] UNC, Dept Oncol, Lineberger Canc Ctr, Chapel Hill, NC USA

[14] UNC, Dept Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[15] IOV Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol Dept, Padua, Italy

[16] Hosp Clin Prov Barcelona, Dept Med Oncol, Barcelona, Spain

[17] Univ Padua, Oncol & Gastroenterol Dept, Dept Surg, Padua, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.276

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

237P

引用

页码：S646 / S646

页数：1

共 50 条

[31] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
Francis W. Hunter
Hilary R. Barker
Barbara Lipert
Françoise Rothé
Géraldine Gebhart
Martine J. Piccart-Gebhart
Christos Sotiriou
Stephen M. F. Jamieson
British Journal of Cancer, 2020, 122 : 603 - 612
[32] CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER
Girish, S.
Gupta, M.
Wang, B.
Lu, D.
Krop, I.
Vogel, C.
Burris, H.
Yi, J.
Saad, O.
Tong, B.
Klencke, B.
Agresta, S.
Chu, W.
Joshi, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S12 - S12
[33] HER2DX genomic test in HER2-positive/hormone receptorpositive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
Guarneri, Valentina
Braso-Maristany, Fara
Vittoria Dieci, Maria
Griguolo, Gaia
Pare, Laia
Marin-Aguilera, Mercedes
Miglietta, Federica
Bottosso, Michele
Alberto Giorgi, Carlo
Blasco, Paula
Castillo, Oleguer
Galvan, Patricia
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Conte, PierFranco
Prat, Aleix
EBIOMEDICINE, 2022, 85
[34] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Bon, Giulia
Pizzuti, Laura
Laquintana, Valentina
Loria, Rossella
Porru, Manuela
Marchio, Caterina
Krasniqi, Eriseld
Barba, Maddalena
Maugeri-Sacca, Marcello
Gamucci, Teresa
Berardi, Rossana
Livi, Lorenzo
Ficorella, Corrado
Natoli, Clara
Cortesi, Enrico
Generali, Daniele
La Verde, Nicla
Cassano, Alessandra
Bria, Emilio
Moscetti, Luca
Michelotti, Andrea
Adamo, Vincenzo
Zamagni, Claudio
Tonini, Giuseppe
Barchiesi, Giacomo
Mazzotta, Marco
Marinelli, Daniele
Tomao, Silverio
Marchetti, Paolo
Valerio, Maria Rosaria
Mirabelli, Rosanna
Russo, Antonio
Fabbri, Maria Agnese
D'Ostilio, Nicola
Veltri, Enzo
Corsi, Domenico
Garrone, Ornella
Paris, Ida
Sarobba, Giuseppina
Giotta, Francesco
Garufi, Carlo
Cazzaniga, Marina
Del Medico, Pietro
Roselli, Mario
Sanguineti, Giuseppe
Sperduti, Isabella
Sapino, Anna
De Maria, Ruggero
Leonetti, Carlo
Di Leo, Angelo
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
[35] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon
Laura Pizzuti
Valentina Laquintana
Rossella Loria
Manuela Porru
Caterina Marchiò
Eriseld Krasniqi
Maddalena Barba
Marcello Maugeri-Saccà
Teresa Gamucci
Rossana Berardi
Lorenzo Livi
Corrado Ficorella
Clara Natoli
Enrico Cortesi
Daniele Generali
Nicla La Verde
Alessandra Cassano
Emilio Bria
Luca Moscetti
Andrea Michelotti
Vincenzo Adamo
Claudio Zamagni
Giuseppe Tonini
Giacomo Barchiesi
Marco Mazzotta
Daniele Marinelli
Silverio Tomao
Paolo Marchetti
Maria Rosaria Valerio
Rosanna Mirabelli
Antonio Russo
Maria Agnese Fabbri
Nicola D’Ostilio
Enzo Veltri
Domenico Corsi
Ornella Garrone
Ida Paris
Giuseppina Sarobba
Francesco Giotta
Carlo Garufi
Marina Cazzaniga
Pietro Del Medico
Mario Roselli
Giuseppe Sanguineti
Isabella Sperduti
Anna Sapino
Ruggero De Maria
Carlo Leonetti
Angelo Di Leo
Journal of Experimental & Clinical Cancer Research, 39
[36] HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in earlystage HER2-positive (HER2+) breast cancer (BC)
Conte, P. F.
Brunet, L. Pare
Braso-Maristany, F.
Chic, N.
Saez, O. Martinez
Dieci, M. V.
Marin, M.
Guarneri, V.
Vivancos, A.
Gonzalez, P. Villagrasa
Parker, J.
Perou, C. M.
Prat, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S609 - S610
[37] An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.
Ponde, Noam Falbel
Ameye, Lieveke
Lambertini, Matteo
Paesmans, Marianne
De Azambuja, Evandro
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[38] Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer
Ponde, Noam
Ameye, Lieveke
Lambertini, Matteo
Paesmans, Marianne
Piccart, Martine
de Azambuja, Evandro
EUROPEAN JOURNAL OF CANCER, 2020, 126 : 65 - 73
[39] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
Quang Anh Le
Bae, Yuna
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
Jacot, W.
Pons, E.
Guiu, S.
Levy, C.
Frenel, J-S
Bachelot, T.
D'Hondt, V.
Firmin, N.
Romieu, G.
Thezenas, S.
Dalenc, F.
CANCER RESEARCH, 2016, 76

← 1 2 3 4 5 →